Predictive role of quantification of myocardial fibrosis using delayed contrast-enhanced magnetic resonance imaging in nonischemic dilated cardiomyopathies: a systematic review and meta-analysis

Aim. The present study aims to provide a systematic review and meta-analysis to investigate the prognostic role of assessing the severity of myocardial fibrosis using delayed contrast-enhanced magnetic resonance imaging in nonischemic dilated cardiomyopathies.

Material and methods. We searched PubMed, Google Scholar for studies that examined the predictive value of quantifying late gadolinium enhancement (LGE) areas in patients with nonischemic dilated cardiomyopathy. Unadjusted hazard ratios (HR) from studies with similar scoring criteria were pooled for meta-analysis.

Results. Nine studies were retrieved from 782 publications for this systematic review and meta-analysis. In total, 2389 patients (mean age, 51,9 years; mean follow-up, 39,3 months) were included in the analysis. Meta-analysis showed the extent of LGE was associated with an increased risk of arrhythmic end point (HR: 1,09/1% LGE; 95% CI: 1,02-1,18; p=0,01), major adverse cardiovascular events (HR: 1,07/1% LGE; 95% CI: 1,01-1,13; p=0,03) and all-cause mortality (HR: 1,09/1% LGE; 95% CI: 1,04-1,13; p<0,0001).

Conclusion. The severity of LGE by cardiac magnetic resonance predicts arrhythmic events (ventricular arrhythmia and sudden death), major adverse cardiovascular events and all-cause mortality. Assessment of LGE can be used as an effective tool for stratifying risk in patients with nonischemic dilated cardiomyopathy.

1. Seferović PM, Polovina MM, Coats AJS. Heart failure in dilated non-ischaemic cardiomyopathy. Eur Heart J Suppl. 2019;21(Suppl M):M40-M43. doi:10.1093/eurheartj/suz212.

2. Cojan-Minzat BO, Zlibut A, Agoston-Coldea L. Non-ischemic dilated cardiomyopathy and cardiac fibrosis. Heart Fail Rev. 2021;26(5):1081-101. doi:10.1007/s10741-020-09940-0.

3. Patel AR, Kramer CM. Role of Cardiac Magnetic Resonance in the Diagnosis and Prognosis of Nonischemic Cardiomyopathy. JACC Cardiovasc Imaging. 2017;10(10 Pt A):1180-93. doi:10.1016/j.jcmg.2017.08.005.

4. Kuruvilla S, Adenaw N, Katwal AB, et al. Late gadolinium enhancement on cardiac magnetic resonance predicts adverse cardiovascular outcomes in nonischemic cardiomyopathy: a systematic review and meta-analysis. Circ Cardiovasc Imaging. 2014;7(2):250-8. doi:10.1161/CIRCIMAGING.113.001144.

5. Alba AC, Gaztañaga J, Foroutan F, et al. Prognostic Value of Late Gadolinium Enhancement for the Prediction of Cardiovascular Outcomes in Dilated Cardiomyopathy: An International, Multi-Institutional Study of the MINICOR Group. Circ Cardiovasc Imaging. 2020;13(4):e010105. doi:10.1161/CIRCIMAGING.119.010105.

6. Kim EK, Lee GY, Jang SY, et al. The Extent of Late Gadolinium Enhancement Can Predict Adverse Cardiac Outcomes in Patients with Non-Ischemic Cardiomyopathy with Reduced Left Ventricular Ejection Fraction: A Prospective Observational Study. Korean J Radiol. 2021;22(3):324-33. doi:10.3348/kjr.2020.0082.

7. Moher D, Liberati A, Tetzlaff J, et al. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLOS Medicine. 2009;6(7):e1000097. doi:10.1371/journal.pmed.1000097.

8. Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. [cited 2021 Sep 17]. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.

9. Cochrane Handbook for Systematic Reviews of Interventions | Cochrane Training [Internet]. [cited 2021 Sep 17]. Available from: https://training.cochrane.org/handbook.

10. Shin DG, Lee HJ, Park J, et al. Pattern of late gadolinium enhancement predicts arrhythmic events in patients with non-ischemic cardiomyopathy. Int J Cardiol. 2016;222:9-15. doi:10.1016/j.ijcard.2016.07.122.

11. Halliday BP, Gulati A, Ali A, et al. Association Between Midwall Late Gadolinium Enhancement and Sudden Cardiac Death in Patients With Dilated Cardiomyopathy and Mild and Moderate Left Ventricular Systolic Dysfunction. Circulation. 2017;135(22):2106- 15. doi:10.1161/CIRCULATIONAHA.116.026910.

12. Halliday BP, Baksi AJ, Gulati A, et al. Outcome in Dilated Cardiomyopathy Related to the Extent, Location, and Pattern of Late Gadolinium Enhancement. JACC Cardiovasc Imaging. 2019;12(8 Pt 2):1645-55. doi:10.1016/j.jcmg.2018.07.015.

13. Lehrke S, Lossnitzer D, Schöb M, et al. Use of cardiovascular magnetic resonance for risk stratification in chronic heart failure: prognostic value of late gadolinium enhancement in patients with non-ischaemic dilated cardiomyopathy. Heart. 2011;97(9):727-32. doi:10.1136/hrt.2010.205542.

14. Neilan TG, Coelho-Filho OR, Danik SB, et al. CMR quantification of myocardial scar provides additive prognostic information in nonischemic cardiomyopathy. JACC Cardiovasc Imaging. 2013;6(9):944-54. doi:10.1016/j.jcmg.2013.05.013.

15. Gulati A, Jabbour A, Ismail TF, et al. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. JAMA. 2013;309(9):896-908. doi:10.1001/jama.2013.1363.

16. Perazzolo Marra M, De Lazzari M, Zorzi A, et al. Impact of the presence and amount of myocardial fibrosis by cardiac magnetic resonance on arrhythmic outcome and sudden cardiac death in nonischemic dilated cardiomyopathy. Heart Rhythm. 2014;11(5):856-63. doi:10.1016/j.hrthm.2014.01.014.

17. Pöyhönen P, Kivistö S, Holmström M, et al. Quantifying late gadolinium enhancement on CMR provides additional prognostic information in early risk-stratification of nonischemic cardiomyopathy: a cohort study. BMC Cardiovasc Disord. 2014;14:110. doi:10.1186/1471-2261-14-110.

18. Behera DR, V K AK, K K NN, et al. Prognostic value of late gadolinium enhancement in cardiac MRI of non-ischemic dilated cardiomyopathy patients. Indian Heart J. 2020;72(5):362-8. doi:10.1016/j.ihj.2020.06.011.

19. Elming MB, Hammer-Hansen S, Voges I, et al. Myocardial fibrosis and the effect of primary prophylactic defibrillator implantation in patients with non-ischemic systolic heart failureDANISH-MRI. Am Heart J. 2020;221:165-76. doi:10.1016/j.ahj.2019.10.020.

20. Fu H, Wen L, Xu H, et al. Prognostic value of multiple cardiac magnetic resonance imaging parameters in patients with idiopathic dilated cardiomyopathy. Int J Cardiol. 2021;325:89- 95. doi:10.1016/j.ijcard.2020.09.079.

21. Ganesan AN, Gunton J, Nucifora G, et al. Impact of Late Gadolinium Enhancement on mortality, sudden death and major adverse cardiovascular events in ischemic and nonischemic cardiomyopathy: A systematic review and meta-analysis. Int J Cardiol. 2018;254:230-7. doi:10.1016/j.ijcard.2017.10.094.

22. Weng Z, Yao J, Chan RH, et al. Prognostic Value of LGE-CMR in HCM: A Meta-Analysis. JACC Cardiovasc Imaging. 2016;9(12):1392-402. doi:10.1016/j.jcmg.2016.02.031.